Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma

MLA

Khang, Minsoo, et al. “Intrathecal Delivery of Nanoparticle PARP Inhibitor to the Cerebrospinal Fluid for the Treatment of Metastatic Medulloblastoma.” Science Translational Medicine, vol. 15, no. 720, Nov. 2023. EBSCOhost, https://doi.org/10.1126/scitranslmed.adi1617.

APA

Khang, M., Lee, J. H., Lee, T., Suh, H.-W., Lee, S., Cavaliere, A., Rushing, A., Geraldo, L. H., Belitzky, E., Rossano, S., de Feyter, H. M., Shin, K., Huttner, A., Roussel, M. F., Thomas, J.-L., Carson, R. E., Marquez-Nostra, B., Bindra, R. S., & Saltzman, W. M. (2023). Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma. Science Translational Medicine, 15(720). https://doi.org/10.1126/scitranslmed.adi1617

Chicago

Khang, Minsoo, Ju Hyun Lee, Teresa Lee, Hee-Won Suh, Supum Lee, Alessandra Cavaliere, Amy Rushing, et al. 2023. “Intrathecal Delivery of Nanoparticle PARP Inhibitor to the Cerebrospinal Fluid for the Treatment of Metastatic Medulloblastoma.” Science Translational Medicine 15 (720). doi:10.1126/scitranslmed.adi1617.